The effects of Topical Insulin on Dry eye disease in Type 2 Diabetic patients
Phase 3
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2024/06/069019
- Lead Sponsor
- Dr Ritika Goel
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Type 2 Diabetes mellitus
Age above 30years
Baseline OSDI score more than 14
Exclusion Criteria
Sjogren syndrome
Already Instilling any eye drops
Use of contact lens
History of ocular Trauma/ chemical injury / ocular surgery
On systemic insulin
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Compare OSDI score and dry eye parameters before and after use of topical insulinTimepoint: Topical insulin given for 8 weeks four times a day and the parameters will be assessed at baseline, 4 weeks and at 8 weeks
- Secondary Outcome Measures
Name Time Method Compare OSDI score & dry eye parameters in topical insulin & artificial tear substitute groupTimepoint: Artificial tears given for 8 weeks four times a day & parameters will be assessed at baseline, 4 weeks at 8 weeks. The results will be compared with topical insulin
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie topical insulin's efficacy in treating dry eye disease in E119 Type 2 diabetes patients?
How does topical insulin compare to cyclosporine A or corticosteroids in managing diabetic dry eye disease?
Which biomarkers correlate with improved tear film stability or corneal nerve regeneration in topical insulin trials for Type 2 diabetes?
What adverse events are associated with topical insulin application in diabetic patients, and how are they mitigated?
Are there synergistic effects of combining topical insulin with anti-VEGF agents or neurotrophic factors for diabetic dry eye treatment?